BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 7, 2026
Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
Substance use and poisoning, BioWorld Science RSS Feed RSS

Substance Use & Poisoning

State University of New Jersey presents new GABA-A receptor PAMs for alcoholism

May 2, 2023
State University of New Jersey (Rutgers) has divulged flavonoids acting as GABA-A receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of alcoholism.
Read More
Neon brain
Substance Use & Poisoning

Discovery and preclinical evaluation of dopamine D4 receptor-selective ligand CAB-01-019

April 14, 2023
Researchers from High Point University recently reported the discovery and preclinical evaluation of a novel class of highly selective dopamine D4 receptor-selective ligands as potential therapeutic candidates for substance use disorders.
Read More
Substance Use & Poisoning

New opioid receptor modulator has the noncompetitive advantage

March 29, 2023
By Anette Breindl
Researchers at Indiana University Bloomington have developed allosteric modulators of the opioid receptor that were superior to the opioid antidote naloxone at blocking the effects of fentanyl in vitro. They presented their work in a session on “Progress towards more efficacious medicine: Antibiotics and antidotes” at the 2023 spring meeting of the American Chemical Society (ACS).
Read More
Illustration of pill being analyzed
Substance Use & Poisoning

Toxicity data reported for VK-4-116 following once-daily oral dosing in rats and dogs

March 27, 2023
Researchers from the National Institutes of Health recently presented preclinical data for the dopamine D3 receptor antagonist VK-4-116, which has potential for the treatment of opioid use disorder (OUD).
Read More
Acetaminophen pills
Substance Use & Poisoning

JNJ-26366821 repairs acetaminophen-induced liver injury in mice

March 23, 2023
Acetaminophen (APAP) is a very common nonprescription analgesic, harmless at low doses, that can cause acute liver injury and even death from acute liver failure when overdosed. The temporal course of acetaminophen overdose-induced liver injury (AILI) can be depicted in two stages – injury and recovery.
Read More
Concept image for radiation syndrome
Substance Use & Poisoning

RNCP selects Redhill's opaganib for evaluation for acute radiation syndrome

March 1, 2023
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the nuclear medical countermeasures product development pipeline as a potential treatment for acute radiation syndrome (ARS).
Read More
Gloved hand holding powder substance in bag
Substance Use & Poisoning

CSX-1004 blocks fentanyl-induced respiratory depression in nonhuman primates

March 1, 2023
Cessation Therapeutics Inc. has announced outcomes of a new study demonstrating that its anti-fentanyl monoclonal antibody treatment, CSX-1004, may provide robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl. The findings come from the company’s ongoing series of proof-of-concept studies in nonhuman primates.
Read More
Substance Use & Poisoning

Aphiotx describes new PANX1 inhibitors for opioid withdrawal

Feb. 9, 2023
Aphiotx Inc. has identified sulfamoyl benzene derivatives acting as pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of opioid withdrawal.
Read More
Illustration of pill being analyzed
Substance Use and Poisoning

Clearmind completes IND-enabling studies for CMND-100 for alcohol use disorder

Dec. 14, 2022
Clearmind Medicine Inc. has completed IND-enabling studies with its 5-methoxy-2-aminoindane (MEAI)-based lead compound, CMND-100, aimed at treating alcohol use disorder (AUD). The company is preparing for an IND submission early next year to the FDA and the Israeli Ministry of Health to start first-in-human phase I/IIa studies in the U.S. and Israel.
Read More
Gastrointestinal

Gut microbiota degrade intestinal nicotine, alleviate smoking-related liver disease

Oct. 19, 2022
By Mar de Miguel
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease (NAFLD) in smokers. In addition to the lung and the brain, nicotine can accumulate in the intestine, where the bacteria Bacteroides xylanisolvens could reduce its concentration and the severity of NAFLD. In their study, published in Nature Oct. 19, 2022, the researchers described the enzymes involved in this process and a new undiscovered pathway.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 118 119 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 6, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • CAR T cell attacking cancer cells

    Development and characterization of anti-CD19 in vivo CAR T therapy

    BioWorld Science
    Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing